Genagon Therapeutics and Mosaique Diagnostics receive Eurostars funding

Genagon Therapeutics and Mosaique Diagnostics receive a prestigious Eurostars grant to jointly undertake major steps towards the transition from the pre-clinical to clinical development of GEN209 - a drug candidate for triple-negative breast cancer (TNBC).

This will be a first-in-class monoclonal antibody-drug conjugate (ADC) targeting Clptm1, a novel molecular target expressed in solid tumors. GAEU Consulting supported the development of the Eurostars grant proposal.

Genagon Therapeutics full press release here: https://lnkd.in/dw8MUqTA

Tomasz Wąsik, MBA comments: “This life science project is an excellent example of a pre-clinical collaboration that meets all the criteria within Eurostars funding program – joint R&D, clear role of each partner and mutual commercial and scientific benefits at the end of the project. I would like to thank both teams for a very good cooperation in the application process”.

Eurostars is the largest international funding programme for SMEs that aim to collaborate on R&D projects that create innovative products, processes or services for commercialisation. The Eurostars project requires a consortium of at least two partners from two different Eureka network countries.